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In this study, we identified antifolates with potent,
targeted activity against whole-cell Mycobacterium
tuberculosis (MTB). Liquid chromatography-mass
spectrometry analysis of antifolate-treated cultures
revealed metabolic disruption, including decreased
pools of methionine and S-adenosylmethionine.
Transcriptomic analysis highlighted altered regula-
tion of genes involved in the biosynthesis and utiliza-
tion of these two compounds. Supplementation with
amino acids or S-adenosylmethionine was sufficient
to rescue cultures from antifolate treatment. Instead
of the ‘‘thymineless death’’ that characterizes folate
pathway inhibition in a wide variety of organisms,
these data suggest thatMTB is vulnerable to a critical
disruption of the reactions centered around S-ad-
enosylmethionione, the activated methyl cycle.
INTRODUCTION
Mycobacterium tuberculosis (MTB), the causative agent of
tuberculosis (TB), is arguably one of the most successful of all
human pathogens. Within recorded history, it is likely the leading
cause of death in Europe and the United States (Bloom and
Murray, 1992). Although the advent of modern diagnostics, anti-
bacterials, and hygiene have dramatically reduced the death rate
from TB in developed nations, MTB still caused 1.3 million
deaths worldwide in 2012 (Zumla et al., 2013)—more than from
any other single bacterial pathogen (Nathan et al., 2008).
Currently, ‘‘short course’’ therapy for TB consists of four
drugs—isoniazid, rifampicin, ethambutol, and pyrazinamide—
that are administered for 2 months, followed by 4 months of
isoniazid and rifampicin (Plorde, 2004). Although highly effective
if taken to completion, this regimen is lengthy, poorly tolerated,
and incompatible with many other medications, including some
antiretrovirals prescribed for the treatment of HIV. Unfortunately,
these issues have frequently led to low rates of completion forChemistry & Biology 21,the full course of treatment (Gough and Kaufman, 2011). The
recent emergence of multidrug-resistant, extensively drug-
resistant, and totally drug-resistant tuberculosis strains further
challenges the utility of the current front-line regimen (Babu
and Laxminarayan, 2012; Gandhi et al., 2006; Velayati et al.,
2009), which has not changed since the inclusion of rifampicin
in 1965 (Williams and Duncan, 2007).
New drugs to treat TB are desperately needed. Ideally, any
new TB drugs would be active following oral administration,
exhibit minimal side effects, be compatible with anti-retroviral
treatments, have activity against strains resistant to other TB
drugs, rapidly clear latent infections, and have pharmacokinetic
and pharmacodynamic properties amenable to relatively infre-
quent dosing.
Antifolates, which interrupt the production of reduced folate
cofactors, are one class of antibacterials with potential to
meet this need (Figure 1). Reduced folate cofactors are used
as one-carbon donors in a wide variety of essential cellular
processes, including the biosynthesis of methionine, serine,
and glycine; purine production; the conversion of deoxyuridine
monophosphate (dUMP) to thymidine monophosphate (dTMP);
and the formation of formyl-methionyl tRNAs in bacteria
(Kompis et al., 2005). Verified drug targets within the folate
pathway include dihydropteroate synthase (DHPS) in bacteria
and dihydrofolate reductase (DHFR) in bacteria, parasites,
and mammals (Hirsch, 1942; Kompis et al., 2005; Potts et al.,
2005).
As early as 1940, promin, a pro-drug of the DHPS inhibitor
dapsone (DDS), was shown to clear MTB infection in guinea
pigs (Barr, 2011). A current second-line therapy for TB, para-
amino salicylic acid (PAS), is also a pro-drug substrate of
DHPS that subsequently poisons as-yet unidentified down-
stream reactions (Chakraborty et al., 2013). Another DHPS inhib-
itor, sulfamethoxazole (SMX), is active against MTB in vitro, with
90% growth inhibition at 8 mg/ml (Wallace et al., 1986). The MTB
DHFR enzyme, encoded by the gene dfrA, is exquisitely sensitive
to the inhibitor methotrexate, but whole-cell MTB is resistant to
killing by this drug (Kumar et al., 2012). WR99210, another inhib-
itor of DHFR, was shown to have bactericidal activity against
whole-cell MTB at 1 mM (Gerum et al., 2002). Additionally, it819–830, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 819
Figure 1. The Folate Pathway and Relevant Inhibitors
(A) The folate pathway in Mycobacterium tuberculosis. Compounds in red are known inhibitors of DHPS and DHFR, respectively.
(B) Test compounds.
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inhibitor trimethoprim and sulfamethoxazole maintains its acti-
vity in culture against some MDR-TB strains (Vilche`ze and Ja-
cobs, 2012). However, there are currently no DHFR inhibitors
used clinically for the treatment of TB.
Structural studies on MTB DHFR have revealed a general fold
similar to the human ortholog, as well as features within the820 Chemistry & Biology 21, 819–830, July 17, 2014 ª2014 Elsevier Lactive site and potential conformational changes that are spe-
cific to MTB (Dias et al., 2014; Li et al., 2000). The possibility
of exploiting unique active site binding, combined with the
demonstrated susceptibility of whole-cell MTB to inhibition by
WR99210, inspired further work to develop antifolates with
activity against MTB. We recently reported a high-throughput
screen for inhibitors of the MTB DHFR enzyme (Kumar et al.,td All rights reserved
Table 1. Activity of Test Compounds against MTB DHFR Enzyme
(IC50) and against Whole-Cell MTB H37Rv or Strains with Altered
DHFR Expression—MIC99
Test
Compound
Mtb DHFR
IC50 (mM)
H37Rv
(mM)
H37Rv::
pMRN1 (mM)
H37Rv:dfrA-
TetON (mM)
WR99210 0.014 1.5–3 30 0.75
Trimetrexate 0.017 6.25 >100 not tested
Trimethoprim 19 >100 not tested not tested
Piritrexim 0.022 >12.5 >100 not tested
Methotrexate 0.0068 >100 >100 25
JSF-1183 0.030 0.6 50 0.08
JSF-1187 0.050 0.2–0.4 >100 0.13
JSF-2104 0.024 33 >100 not tested
JSF-2105 0.172 33 >100 not tested
In H37Rv::pMRN1, dfrA expression levels are approximately 8 times wild
type, whereas in the absence of tetracycline, dfrA expression levels in the
H37Rv:dfrA-TetON are approximately 0.3 times wild type.
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methotrexate derivatives (Figure 1) with activity against MTB.
In addition, we describe the molecular consequences associ-
ated with folate pathway disruption in MTB. Unlike the ‘‘thymine-
less death’’ associated with folate pathway inhibition in many
other organisms, we find that MTB undergoes specific perturba-
tion in reactions that produce and utilize S-adenosylmethionine,
collectively known as the activated methyl cycle (Halliday et al.,
2010; Parveen and Cornell, 2011).
RESULTS
MTB Strains with Altered dfrA Expression
To differentiate between compounds targeting DHFR and those
aimed at other targets, we created strains with altered expres-
sion of dfrA. H37Rv::pMRN1 has two copies of dfrA, resulting
in overexpression of the cognate mRNA. The second copy was
introduced via the integrating plasmid pMRN1, which contains
the MTB dfrA sequence driven by the high-level constitutive
MOP promoter. Transformants were identified using kanamycin
selection and nearly 8-fold dfrA overexpression was confirmed
via quantitative RT-PCR (qRT-PCR) (data not shown). We also
created H37Rv:dfrA-TetON, in which the native dfrA promoter
was swapped for an artificial promoter responsive to tetracy-
cline. In the absence of tetracycline, expression of dfrA is
approximately 30% of wild-type levels (Kumar et al., 2012). An
anti-DHFR antibody was not available to determine the degree
of altered expression at the protein level, but the results below
strongly suggest that DHFR levels are in fact altered as expected
in these strains.
WR99210 Targets MTB DHFR
Previously published studies have demonstrated not only that
the triazine antimalarial WR99210 binds to and inhibits the
MTB DHFR enzyme, but also that it inhibits the growth of
MTB at approximately 1 mM (Gerum et al., 2002; Li et al.,
2000). However, the unusually low rate of resistant mutants
(<1.2 3 1010) suggested that WR99210 might have multiple-Chemistry & Biology 21,or off-target effects in MTB (Gerum et al., 2002). To confirm
that the observed activity of WR99210 resulted from inhibition
of DHFR, minimum inhibitory concentrations (MICs) were
compared between wild-type H37Rv and the dfrA over- and
underexpressor strains. The MICs increased in the overexpres-
sor and decreased in the underexpressor, showing that sensi-
tivity to WR99210 is materially linked with intracellular levels
of DHFR (Table 1).
Test Compounds Exhibit Activity against H37Rv
To evaluate the susceptibility of MTB to antifolates, select com-
pounds were assayed for their ability to inhibit growth of the
wild-type MTB strain H37Rv (Table 1). These compounds
included commercially available antifolates, as well as metho-
trexate analogs that to the best of our knowledge have not pre-
viously been tested against MTB. Of the commercially available
antifolates tested, piritrexim and trimetrexate both showed ac-
tivity targeting the folate pathway, as evidenced by potent inhi-
bition of the MTB DHFR enzyme in vitro and the shift in MIC in
the DHFR overexpressor strain (Table 1). As expected, metho-
trexate and trimethoprim showed no activity against whole-
cell MTB. Although trimethoprim’s lack of whole-cell activity
may be attributed to its relatively poor inhibition of DHFR
(IC50 = 19 mM), methotrexate is a potent DHFR inhibitor
(IC50 = 6.8 nM). Cognizant of previous efforts outside of the
anti-infectives realm (Rosowsky 1973), we also synthesized
and tested analogs of methotrexate. We harnessed published
chemical methods (Dawson et al., 1987; Piper and Montgom-
ery, 1977; Rosowsky, 1973) to prepare the dimethyl (JSF-
1187) and diethyl (JSF-1183) esters of methotrexate and
demonstrated that they inhibit DHFR with IC50 values of 50
and 30 nM, respectively. Unlike methotrexate, however, the
esters also exhibited significant potency against whole-cell
MTB (MIC = 600 nM for JSF-1183 and 200–400 nM for JSF-
1187). Critically, the MIC values increased approximately two
orders of magnitude when dfrA was overexpressed and
decreased approximately 10-fold when dfrA expression was
reduced (Table 1). To investigate the active species within cells,
we first measured intracellular compound levels by mass
spectrometry and found a mixture of parent compound, each
mono-ester, and some methotrexate (data not shown). We
then synthesized and tested both mono-ethyl esters (JSF-
2104 and JSF-2105). Each of these compounds had weak but
measurable activity on MTB, whereas neither showed improved
activity on the DHFR enzyme (Table 1).
WR99210 and JSF-1187 Are Effective against Clinical
MTB Strains
Isolated in 1905, H37Rv is a laboratory strain of MTB that retains
full virulence in animal models (Cole et al., 1998); however, there
are likely significant differences between currently circulating
strains of MTB and H37Rv (Ioerger et al., 2010). To test whether
clinical strains might be similarly susceptible to growth inhibition
by antifolates, a panel of five circulating MTB strains was treated
with JSF-1187 and WR99210. All the strains tested were known
to be pan-sensitive to current antitubercular drugs. Although
there was some divergence in the observed MICs, all strains
were susceptible to both WR99210 and JSF-1187 at levels
similar to H37Rv (Table S1 available online).819–830, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 821
Figure 2. DHFR and DHPS Inhibitors Behave Synergistically in Cul-
ture against MTB
Each point represents a combination of drug concentrations that result in an
MIC level of inhibition. All combinations shown were synergistic. The results
shown are representative of at least three replicate experiments.
(A) JSF-1187 and dapsone. FIC = 0.47.
(B) JSF-1187 and sulfamethoxazole. FIC = 0.54.
(C) WR99210 and dapsone. FIC = 0.45.
(D) WR99210 and sulfamethoxazole. FIC = 0.49.
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In other systems, it is well established that the combination of
DHFR and DHPS inhibitors can result in synergy that reduces
the rate at which resistance develops while decreasing the total
amount of drug that must be used, potentially minimizing the risk
of unwanted side effects (Bushby, 1975). To assesswhether syn-
ergy also occurs in MTB, the DHFR inhibitors JSF-1187 and
WR99210 were each combined with the DHPS inhibitors SMX
(Wallace et al., 1986) and DDS (Karlson, 1963).
A traditional checkerboard titration format (Elion et al., 1954)
was used to determine a fractional inhibitory concentration
(FIC) for each set of compounds, where FIC is defined as the
sum of the [concentration of each agent in combination]/[con-
centration of each agent individually] for both agents at a given
level of inhibition. An FIC of 1 denotes an additive effect, whereas
an FIC greater than 1 represents an antagonistic relationship and
an FIC less than 1 represents a synergistic relationship between
compounds. For all four compound combinations tested, the FIC
was approximately 0.5, signifying synergy (Figure 2). JSF-1187
and WR99210 were also tested for synergy with the antimyco-
bacterials isoniazid, streptomycin, kanamycin, and rifampicin;
additive relationships were observed for all such combinations
(data not shown).
Exposure toAntifolates Leads toDownstreamMetabolic
Disruption
To probe the metabolic effects of these compounds in MTB,
metabolite levels were quantified following treatment with822 Chemistry & Biology 21, 819–830, July 17, 2014 ª2014 Elsevier LWR99210 using LC-MS-based methods (de Carvalho et al.,
2010b). Cells were grown on nitrocellulose filters and exposed
to drug at 0.8, 20, and 100 mM (approximately 0.253, 73, and
333 MIC) for 0, 4, and 24 hr. Cells were then rapidly quenched
in a cold acetonitrile/methanol mixture and lysed. Ion profiles
were generated and queried for 168 chromatographically
resolved m/z species corresponding to known metabolites, of
which 92 were detected (Table S2). For 80% of these peaks,
there was little or no change in metabolite abundance following
treatment. As expected, abundance of the m/z species corre-
sponding to WR99210 increased with both time and concentra-
tion (data not shown). Increased WR99210 concentrations and
longer exposure times were associated with increased metabo-
lite dysregulation.
Twelve chromatographically resolved m/z species produced
peaks whose relative abundance increased more than 2-fold
in duplicate experiments, whereas six produced peaks whose
relative abundance decreased more than 2-fold in both experi-
ments (Table S2). Where available, we used coelution with
chemical standards to confirm select metabolite identities and
the method of standard addition to calculate metabolite con-
centrations. The largest increases were observed for 5-aminoi-
midazole-4-carboxamide ribonucleotide (AICAR) and dUMP
(40- and 30-fold, respectively), and the largest decrease was
for S-adenosylmethionine (SAM, at least 20-fold, to the limit of
detection; Figure 3A). Other metabolites (and/or their corre-
sponding masses) that changed in concentration include
homocysteine, S-ribosylhomocysteine, S-methylthioadenosine,
lysine, serine, methionine, and uracil. The kinetics of metabolite
disruption were also noteworthy (Figure 3B). Homocysteine
levels increased within 4 hr, suggesting that reduced folate
pools were already depleted. Methionine concentrations were
halved at 4 hr but showed no change after that. In contrast,
SAM levels were barely affected after 4 hr and then dropped
substantially by 24 hr. At no time were significant changes in
metabolite concentration observed for thymine, adenine, gua-
nine, adenosine, or glycine.
In aggregate, exposure to WR99210 produced a striking
pattern of metabolic disruption, with an emphasis on species
associated with the active methyl cycle, reactions that produce
or utilize S-adenosylmethionine. To assess which features of
this pattern were shared by exposure to other antifolates, metab-
olomics experiments were also conducted with JSF-1183 and
JSF-1187. MTB cells were grown on nitrocellulose filters, treated
with 25 mM (333 MIC) of each compound for 24 hr, and then
processed for metabolomic analysis as above. Treatment with
JSF-1183 or JSF-1187 each produced disruptions in core folate
metabolites remarkably similar to those seen following exposure
to WR99210. Key metabolites affected by WR99210 all trended
in the same directions following treatment with JSF-1183 or JSF-
1187. In particular, homocysteine and AICAR were highly
induced, whereas SAM levels were highly depleted by all three
drugs. The patterns were not absolutely identical; dUMP was
more powerfully induced by WR99210, whereas methionine
levels were decreased to a greater extent following treatment
with JSF-1183 and JSF-1187. Such modest differences in
metabolite levels following 24 hr of exposure to drugs are not
surprising, and the overall pattern is similar enough to define a
metabolic signature of antifolate inhibition in MTB.td All rights reserved
Figure 3. Treatment of MTB with WR99210 Leads to Concentration-Dependent and Time-Dependent Metabolic Disruptions
(A)WR99210 disruptsmetabolite pools in a concentration-dependent fashion. Cells were treated for 24 hr withWR99210 at 0.8, 20, and 100 mM (0.253, 73, and
333 MIC), and the data represent the fold change relative to time zero.
(B) WR99210 disrupts metabolite pools in a time-dependent fashion. Conversion of homocysteine to methionine depends on the availability of reduced folate
cofactors (indicated by red bars). Metabolites were identified by LC-MS (see Experimental Procedures), and putative metabolite identities were based on ac-
curate mass (m/z) and chromatographic retention time matching. In most cases, metabolite identities were confirmed using chemical standards demonstrating
coelution with experimental samples, and levels are expressed as the ratio of metabolite concentration compared to untreated cells. For AICAR, S-ribosylho-
mocysteine and S-methylthioadenosine, levels are expressed as the ratio of signal intensity compared to untreated cells. The results are representative of two
independent experiments, with three technical replicates per experiment. S-Adenosylhomocysteine could not be detected in these experiments.
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within the Activated Methyl Cycle
Microarray analysis was used to track mRNA levels following
DHFR inhibition. Cultures were grown to early log phaseChemistry & Biology 21,(OD600 = 0.1) and then exposed to WR99210, JSF-1183, or
JSF-1187, each at30 times the MIC, the highest concentration
used for metabolomic analysis. 10 ml aliquots were taken before
drug treatment and after 24 hr of exposure. The RNAwas purified819–830, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 823
Chemistry & Biology
Folate Pathway Disruption in M. tuberculosisfrom these samples and labeled with fluorescent probes, and
then transcript abundance was quantified by hybridization to
custom Nimblegen tiling arrays with 135,000 probes covering
the MTB H37Rv genome (Minch et al., 2012). Gene expression
changes were considered significant if they produced a moder-
ated t test p < 0.01 and a 2-fold change after Benjamini Hoch-
berg multiple testing correction.
After 24 hr of treatment, a large number of genes were differ-
entially regulated in response to each of the drugs, leading to up-
regulation of 300–500 genes and downregulation of 300–900
genes. The response to the three drugswas strikingly consistent;
245 genes were upregulated, and 312 were downregulated in all
three treatments. The full data set is available online (NCBI GEO
accession number GSE55979).
Expression changes were dominated by broad downregula-
tion of basic cellular processes. Almost 70%of the genes encod-
ing ribosomal proteins were downregulated, along with ATP
synthase-related genes and the genes involved in cell division
(ftsEQWXY). Also downregulated were nearly all of the NADH-
dehydrogenase complex I genes and genes of the mce1 and
mce4 loci. thyX, which encodes the flavin-dependent alternate
thymidylate synthase, was also modestly downregulated.
Biosynthetic pathways for several amino acids were downregu-
lated, including those involved in arginine, asparagine, and tryp-
tophan biosynthesis. The set of downregulated genes also
included seven methyltransferases known to be dependent on
S-adenosylmethionine. These genes produce proteins used in
a variety of metabolic pathways, including mycolic acid biosyn-
thesis, RNA methylation, and production of phenolic glycolipids
and pthiocerol dimycocerosates.
Against this backdrop of broad downregulation, the genes
required for production of methionine and SAM were markedly
upregulated (Figure 5). The genesmetA andmetC were upregu-
lated 15-fold, making them 2 of the 10 most strongly upregu-
lated genes. Transcript levels of the methionine synthase gene
metH and the SAM synthase gene metK increased 3-fold and
nearly 2-fold, respectively. In contrast, genes associated with
SAM utilization, including speE, mtn, and Rv2952, were among
those repressed by antifolate treatment.
Supplementation with Serine/Methionine/Glycine, or
with S-Adenosylmethionine, Rescues MTB from
Antifolate Treatment
Supplementation assays have long been used as tools to under-
stand the effects of drug treatment and pathway inhibition in a
variety of organisms (Daniel et al., 1947). To probe the effects
of folate pathway inhibition in MTB, we supplemented MTB
cultures exposed to MIC levels of WR99210 or JSF-1187
with a variety of metabolites. Nucleosides, folic acid, leucovorin
(5-formyl-tetrahydrofolate), and dTMP all failed to alter cell
survival at concentrations up to 1 mM (data not shown). How-
ever, MTB lacks the annotated enzymes required to assimilate
exogenous folate species (Fivian-Hughes et al., 2012) and is un-
likely to efficiently transport phosphorylated nucleotide species
across its thick and hydrophobic cell envelope.
The folate pathway is directly involved in the metabolism of
three amino acids (Figure 1). The serine hydroxymethyltrans-
ferases GlyA1 and GlyA2 use serine as the methyl donor to pro-
duce 5,10-methylene-tetrahydrofolate from tetrahydrofolate.824 Chemistry & Biology 21, 819–830, July 17, 2014 ª2014 Elsevier LThe reverse reaction transfers the methyl group from 5,10-meth-
ylenetetrahydrofolate to glycine, regenerating tetrahydrofolate.
Another reduced folate cofactor, 5-methyltetrahydrofolate, is
the methyl donor for the production of methionine from homo-
cysteine. When cultures treated with MIC-level concentrations
of WR99210 were grown in media supplemented with combined
serine/methionine/glycine, cell growth was restored to approxi-
mately 75% of untreated cells (Figure 6A). A similar rescue
from inhibition by DDS, SMX, WR99210, and JSF-1187 was
observed when cells were grown in media containing all 20
L-amino acids (data not shown). However, when cultures were
supplemented with a full amino acid mixture lacking serine,
methionine, and glycine, there was no rescue from antifolate
treatment (Figure 6B). There was also no rescue observed
when treated cultures were grown on media containing D-amino
acids (Figure 6D). As expected, supplementation with amino
acids did not affect the outcome of treatment with isoniazid, an
inhibitor of MTB cell wall biosynthesis (data not shown).
To test the hypothesis that antifolate treatment leads to a critical
depletion of methionine derivatives, we also supplemented
WR99210-treated cultures with S-adenosylmethionine (Fig-
ure 6C). Supplementation with 80 mM SAM restored growth to
approximately 50% that of untreated cultures, and growth was
completely restored at 320 mM SAM. However, supplementation
withmethioninealonewasunable to restoregrowthofcells treated
with either WR99210 or JSF-1187 (data not shown). Altogether,
these results suggest that disruption of the activatedmethyl cycle,
rather than perturbation of folate-dependent amino acid levels, is
the critical consequence of folate pathway disruption.
DISCUSSION
In an effort to identify antifolates with antitubercular properties,
we explored methotrexate as a scaffold. Although methotrexate
is inactive against whole-cell MTB, themethotrexate dialkyl ester
analogs JSF-1187 and JSF-1183 exhibited MIC values between
200 and 600 nM against H37Rv (Table 1). JSF-1187 was also
tested and found active against a panel of MTB clinical isolates
(Table S1). Although the mechanistic rationale for this increase
in activity remains unresolved, a plausible explanation is that
JSF-1183 and JSF-1187 benefit from improved target access.
The alkylations afford more lipophilic molecules that may pene-
trate the hydrophobic mycobacterial cell wall better than metho-
trexate, which should form a dianion under assay conditions.
These substitutions may also interfere with polyglutamylation
of the molecule (Kwon et al., 2008), although polyglutamylation
of methotrexate has traditionally been associated with increased
compound retention within the cell and increased affinity for
DHFR (Liani et al., 2003). Additionally, the mono- and di-esters
do not display improved inhibition of DHFR but show a 4- to
25-fold decrease in DHFR enzyme inhibition in vitro (Table 1).
Similar trends were observed in inhibition studies using DHFR
from rabbit, mouse, and Trypanosoma cruzi (Rosowsky et al.,
1978). A plausible scenario is that the methotrexate esters are
sufficiently lipophilic and stable to penetrate the cell wall and
then inhibit DHFR through a combination of the dialkyl ester,
one or both mono-esters, and methotrexate.
Part of the rationale for studying antifolates in MTB is the
wealth of information available about these molecules in othertd All rights reserved
Figure 4. The Signature of Antifolate Inhibi-
tion in MTB
(A) Map of the core folate metabolome, with key
metabolites that collectively comprise the signa-
ture of folate pathway disruption circled in red.
DHF, dihydrofolate; THF, tetrahydrofolate.
(B) The signature of folate pathway disruption.
MTB cells were treated with JSF-1183 or JSF-
1187 at 100 mM for 24 hr, and results for core folate
pathway metabolites were compared with those
shown above for WR99210. Metabolite signal in-
tensities were normalized to internal control me-
tabolites. Results shown are on a log2 scale and
are representative of two independent experi-
ments, with three technical replicates per experi-
ment. Metabolite identities were confirmed using
chemical standards demonstrating coelution with
experimental samples, with the exception of
AICAR.
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display synergy with the DHPS inhibitors dapsone and sulfa-
methoxazole (Figure 2), consistent with data from Plasmodium
and other bacteria (Bushby, 1975). However, we also show
that the downstream consequences of folate inhibition in MTB
differ substantially from the model developed primarily in Plas-
modium and Escherichia coli. In particular, our data are not
consistent with the ‘‘thymineless death’’ scenario that is the hall-
mark of antifolate treatment in other organisms (Ahmad et al.,
1998; Hartman, 1993; Huennekens, 1996).
Antifolates restrict cellular metabolism at several discrete
steps (Figure 4). Thymineless death describes a process in which
antifolate-generated thymine starvation leads to increased rates
of erroneous uridine incorporation into DNA and a subsequent
accumulation of fatal single- and double-stranded breaks
(Ahmad et al., 1998; Sangurdekar et al., 2011). This idea was
originally proposed after experiments in which bacteria treated
with antifolates were rescued by thymine supplementation
(Amyes and Smith, 1974). Recent analyses support this concept,
showing a rapid and significant drop in dTMP/thymidine/thymine
levels in E. coli and Plasmodium falciparum following antifolate
treatment (Kwon et al., 2010; Yeo et al., 1997), although antifo-
lates produce other metabolic disruptions as well. For example,
in E. coli treated with antifolates, the glycine pool is depleted 10-
fold within 5 min, and methionine levels decrease 85% within
30 min, whereas most amino acid levels gradually increase
(Kwon et al., 2010). In fact, when amino acid levels are low,
E. coli is rescued from the bactericidal effects of thymineless
death by a RelA-mediated stringent response (Kwon et al.,
2010). In MTB, however, the picture is quite different. We see
little evidence to support the thymineless death scenario, and
instead, our metabolomics, transcriptomics, and supplementa-
tion experiments are all consistent with a disruption in the acti-
vated methyl cycle.
Following antifolate treatment, our LC-MS experiments re-
vealed limited disruption of MTB metabolite pools (Figures 3
and 4). Even after 24 hr of treatment with WR99210 at 333
MIC, the putative thymine and glycine pools, as well as 80% of
all compounds assayed, were unperturbed. Many of the metab-
olites that do change are linked to the activated methyl cycle.
Comparing metabolite profiles following treatment with threeChemistry & Biology 21,antifolates revealed striking similarities, including substantial
increases in AICAR and homocysteine and a drop in levels of
SAM and methionine (Figure 4). These changes are accompa-
nied by consistent shifts in expression of the relevant genes (Fig-
ure 5). Exposure to the DHPS substrate and TB drug PAS yields a
very comparable metabolic profile (Chakraborty et al., 2013),
suggesting that this pattern reflects a signature of folate pathway
inhibition in MTB.
Supplementation experiments also produced a unique
response in MTB. It is not surprising that supplementation with
thymidine and dTMP failed to support bacterial growth after
treatment with WR99210 and JSF-1187. MTB lacks an obvious
homolog to thymidine kinase and thus cannot convert exoge-
nous thymidine into the dTMP needed for DNA incorporation
(Fivian-Hughes et al., 2012). Additionally, the relatively imperme-
able mycobacterial cell wall is likely to limit the movement of
dTMP into the cell, even when levels in the growth media are
high (Nguyen and Thompson, 2006). However, addition of SAM
or a combination of serine, methionine, and glycine reversed
the inhibitory effects of antifolates in MTB (Figure 6). In contrast,
amino acid supplementation enhances antifolate killing in E. coli
(Kwon et al., 2010).
Altogether, our experiments suggest a model where methio-
nine pools are depleted by antifolate treatment, whereas SAM
pools are protected out to 4 hr of treatment. At some point, how-
ever, methionine levels stabilize, and other components of the
activated methyl cycle are allowed to deplete. Continued flux
through the activated methyl cycle is indicated by the drop in
SAM and the increase in levels of putative S-ribosylhomocys-
teine (one of the end products of SAM demethylation) between
4 and 24 hr (Figure 3). We were unable to detect S-adenosylho-
mocysteine, a feedback inhibitor of many SAM-dependent
methyltransferases (Reddy et al., 2008), although it seems likely
that it accumulates as well. In multiple cell lines, perturbation of
the ratio of SAM and SAH, typically maintained at 10:1, leads to
growth arrest (Reddy et al., 2008). Whether such a mechanism
exists in MTB and is induced following antifolate treatment re-
mains to be seen.
Disruption of the activated methyl cycle should have multiple
consequences. SAM is an integral donor of reactive methyl
groups essential for cellular processes such asDNAmethylation,819–830, July 17, 2014 ª2014 Elsevier Ltd All rights reserved 825
AB
Figure 5. Treatment with Antifolates Leads
to Altered Expression of Genes of the Acti-
vated Methyl Cycle
Cells were treated with WR99210, JSF-1183, or
JSF-1187 at 333 MIC for 24 hr. RNA was ex-
tracted from treated cells, and labeled probes
were hybridized to custom Nimblegen arrays.
(A) Map of the activated methyl cycle, with relevant
MTB genes and compounds (in boxes).
(B) Fold change in expression of activated methyl
cycle genes following antifolate treatment. Results
shown are the averages of three independent
biological replicates.
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Folate Pathway Disruption in M. tuberculosispolyamine biosynthesis, and biotin production (Parveen and
Cornell, 2011). In MTB, the SAM-dependent methyltransferase
Hma catalyzes the formation of both keto- andmethoxy-mycolic
acids (Boissier et al., 2006); another SAM-dependent methyl-
transferase, Rv2952, is responsible for the unique phthiocerol
dimycocerosates and phenolic glycolipids found in the Beijing
family of MTB strains (Huet et al., 2009). SAM is also necessary
for proper methylation of ribosomal RNAs in MTB (Kumar et al.,
2011; Rahman et al., 2010). Depletion of SAM pathway compo-
nents likely disrupts these essential cellular reactions, as well as
others that are not yet appreciated.826 Chemistry & Biology 21, 819–830, July 17, 2014 ª2014 Elsevier Ltd All rights reservedOur current experiments cannot defini-
tively exclude the possibility that starva-
tion for dTMP plays a role in the death of
MTB following antifolate treatment.
Consistent with the thymineless death
scenario, the MTB genes induced by
exposure to antifolates include several
associated with DNA repair (NCBI GEO
accession number GSE55979). We also
observe a 30-fold increase in dUMP after
24 hr of treatment withWR99210 at333
MIC. Unfortunately, we were unable to
measure dTMP or thymidine at any time
point, although thymine levels remained
unchanged. It should be noted, however,
that MTB is unusual in possessing two
thymidylate synthase enzymes (Figure 1).
ThyA, a canonical thymidylate synthase,
uses 5,10-methylene-tetrahydrofolate as
both methyl donor and reductant. ThyX,
a flavin-dependent thymidylate synthase,
uses 5,10-methylene-tetrahydrofolate as
methyl donor and FADH2 as reductant
(Fivian-Hughes et al., 2012). This unique
pairing may skew the response to folate
pathway inhibition away from thymidylate
starvation and toward the depletion of
methionine derivatives.
Antifolates are an attractive class of
inhibitors, whose potential for treating
TB has yet to be realized. Increased un-
derstanding of the effects of folate
pathway inhibition should allow rationaldesign of better inhibitors and combinations. Although the folate
pathway has been the subject of study for over 50 years, it is
becoming clear that the established paradigms may not entirely
apply to MTB, providing us with unique challenges to confront
and unique opportunities to exploit.
SIGNIFICANCE
New agents to combat tuberculosis (TB) are badly needed,
yet one of the world’s most utilized drug targets—folate
pathway inhibition—is not a part of front line TB
Figure 6. Supplementation with Amino
Acids or S-Adenosylmethionine Rescues
MTB from Treatment with WR99210
MTB constitutively expressing GFP as a reporter
for growth was treated with 780 nM WR99210
(white bars) or 1% DMSO (no drug control; gray
bars) and supplemented with serine/methionine/
glycine (A), amino acids (minus serine/methionine/
glycine) (B), S-adenosylmethionine (C), and
D-amino acids (D). The results shown are the
means of two technical replicates ± SD. All results
were confirmed by optical density (data not
shown). RFU, relative fluorescence units.
(A and B) Graphs show representative data from
three to five experiments.
(C and D) Graphs show representative data from
two experiments.
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Folate Pathway Disruption in M. tuberculosischemotherapy, and widely used antifolates methotrexate
and trimethoprim are inactive on M. tuberculosis (MTB) in
culture. In this study, however, we identified antifolate
variants of methotrexate with good activity versus MTB di-
hydrofolate reductase in vitro and potent activity against
whole-cell MTB. Metabolomic analysis of antifolate-treated
cultures revealed unique metabolic disruptions, including
decreased pools of methionine and S-adenosylmethionine.
Gene expression analysis highlighted altered regulation of
genes involved in the biosynthesis and utilization of these
two compounds. Supplementation with amino acids or
S-adenosylmethionine was sufficient to rescue cultures
from antifolate treatment. These data contrast substantially
with the well-studied effects of folate pathway inhibition in
other organisms. Instead of the ‘‘thymineless death’’ that
characterizes antifolate addition in E. coli, Plasmodium,
and other systems, these data suggest that MTB is vulner-
able to a critical disruption of the reactions centered around
S-adenosylmethionione, the activated methyl cycle. As a
result, folate pathway inhibition in MTB may present novel
opportunities and challenges for drug development.EXPERIMENTAL PROCEDURES
Bacterial Strains and Growth Conditions
Unless otherwise indicated, liquid cultures of mycobacteria were grown in 7H9
media supplementedwith 0.05%Tween 80 and albumin, dextrose, and catalase
(ADC;BectonDickinson)oronMiddlebrook7H10platessupplementedwitholeic
acid, ADC at 37C. For metabolomic analysis cultures were grown on Middle-
brook 7H10 plates supplemented with 5% bovine serum albumin, 2% dextrose,
and 0.85% NaCl. Strains were grown to an optical density (OD600) of approxi-
mately 1 and stored at80C in 15% glycerol. If needed, kanamycinwas added
at 30 or 50 mg/ml for mycobacteria and E. coli, respectively. H37Rv (American
Type Culture Collection 25618) was used as the Mycobacterium tuberculosisChemistry & Biology 21, 819–830, July 17, 2014wild-type strain, whereas E. coli DH5-a (Invitrogen)
was used for cloning. H37Rv::pHigh22, bearing gfp
driven by a strong 16S rRNA promoter, was used
for all assays using a fluorescent read-out.
Construction of MTB Strains with Altered
dfrA Expression
For the constitutively overexpressing construct
pMRN1, PCR-amplified MTB dfrA sequence wascloned into the shuttle vector pJEB402 downstream of the mycobacterial
constitutive promoter MOP (George et al., 1995). This vector integrates into
the MTB chromosome at the phage L5 attachment site (Lee and Hatfull,
1993). DNA was isolated from E. coli transformants and introduced into MTB
via electroporation as previously described (Park et al., 2003; Wards and
Collins, 1996). Kanamycin was used to select for transformants, and qRT-
PCR was used to quantify the level of dfrA overexpression. Construction of
the strain H37Rv:dfrA-TetON used for underexpression in the absence of
tetracycline was described previously (Kumar et al., 2012).
Expression and Purification of MTB-DHFR
Competent E. coli BL21 (DE3) cells (Novagen) were transformed with recom-
binant plasmid containing dfrA gene and grown at 37C to OD600 of 0.7 in
LB medium containing 70 mg/ml of kanamycin. The cells were cooled to
20C and equilibrated for an hour, and protein expression was induced by
the addition of 0.8 mM IPTG. After an overnight induction, the cells were
spun down at 4,000 rpm. The pellet was resuspended in the buffer (20mM trie-
thanolamine [TEA], 30 mM imidazole, 50 mMKCl [pH 7.8]) containing protease
inhibitor cocktail (Novagen), 20mg of egg white lysozyme (Sigma), and 5 of mg
bovine pancreas DNase I. The resuspended cells were disrupted by cell lysis
machine and were spun down at 16,000 rpm for 50 min to remove the cell
debris. The supernatant, filtered through 0.22 mm, was applied to a 15 ml
column of high performance HisTrap column (GE Healthcare) pre-equilibrated
by the loading buffer (20mMTEA, 30mM imidazole, 300mMKCl [pH 7.8]). The
cell-loaded column was washed with extensive amounts of the loading buffer
and then eluted with a linear gradient (350 ml) from 0% to 100% of elution
buffer (20 mM TEA, 500 mM imidazole, 300 mM KCl [pH 7.8]). The pure
DHFR-containing fractions were pooled and concentrated down to 4 ml and
treated with 30 ml of thrombin (Novagen) at 16C for 3 days. The cleaved
protein was passed through a 5 ml HisTrap HP column (GE Healthcare) pre-
equilibrated with the loading buffer. The unbound protein was collected,
dialyzed against 4 l of dialysis buffer (25 mM potassium phosphate, 50 mM
KCl, 0.1 mM EDTA, 5% glycerol [pH 7.2]) for 6 hr, and concentrated down to
15 mg/ml.
In Vitro Assay for MTB-DHFR
The enzyme assay for Mtb DHFR was performed in 100 mM HEPES, 50 mM
KCl (pH 7.0) at 25C. The absorbance decrease at 340 nm, representing theª2014 Elsevier Ltd All rights reserved 827
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Folate Pathway Disruption in M. tuberculosisconsumption of NAPDH, was monitored with a Cary 50 spectrophotometer.
The inhibitors at various concentrations (20 nM of DHFR and 40 mMof NADPH)
were added in a 1 ml cuvette, and the reaction was initiated by the addition of
35 mM of dihydrofolate. The calculated IC50 values for trimethoprim and meth-
otrexate are consistent with those previously reported in the literature (White
et al., 2004).
IC50 Determination
20 nM of DHFR was incubated with 40 mM of cofactor NADPH and seven or
eight different concentrations of the inhibitor (where applicable) for 1 min.
The reaction was initiated by the addition of 35 mM dihydrofolate. The reaction
progress was measured for 2 min, and the linear region was used for
measuring the initial velocity parameters. Percent inhibition values from
different concentration points were acquired and analyzed by a curve-fitting
program supported by Collaborative Drug Discovery.
Preparation of Test Compounds
WR99210 was kindly provided by Jacobus Pharmaceuticals. Synthesized
compounds are designated as JSF-####. Trimetrexate, trimethoprim, metho-
trexate, piritrexim, sulfamethoxazole, and dapsone were purchased from
commercial sources. All compounds were dissolved in DMSO. All drug ali-
quots were stored at 20C until immediately before use.
Assessment of Antitubercular Activity
MTB cultures were grown to mid-log phase and then diluted to a calculated
starting OD600 of 0.001 and aliquoted into 96-well plates. Test compounds in
DMSO were added at 1% of total volume. A 1:100 dilution was used to deter-
mine the MIC cutoff for each assay. Plates were incubated for 7 days at 37C.
The BacTiter-Glo Microbial Cell Viability Kit (Promega) was used to measure
intracellular ATP levels as a proxy for cell survival and growth. Cultures were
incubated with reconstituted, room temperature BacTiter-Glo Reagent for
10–20 min prior to luminescence quantification by a FLUOStar Omega plate
reader. MICs were confirmed with an MTB H37Rv strain that constitutively ex-
presses GFP. Growth was monitored by quantitating fluorescence (excitation:
485 nm; emission: 520 nm) using the FLUOStar Omega plate reader.
Metabolomic Sample Preparation
For metabolomic analysis samples were prepared according to previously
published procedures (de Carvalho et al., 2010a). In short, MTB was grown
to mid-log phase and then diluted to an OD600 of 0.1. A 1 ml culture was
then inoculated onto 22 mm 0.2 mm nitrocellulose filters (Millipore) using
vacuum filtration, placed on 7H10+ADN plates, and incubated at 37C. On
day 5 postinoculation, theMTB-laden filters were transferred to plates contain-
ing appropriate concentrations of drug. At appropriate times, cell metabolism
was quenched by freezing MTB-laden filters in 40C acetonitrile:metha-
nol:H2O (40:40:20). Cells were lysed by bead beating, with cooling on ice
between steps, and the extracts purified by centrifugation and 0.22 mm filtra-
tion. Each technical replicate combined the biomass from eight nitrocellulose
filters, and an experiment included three technical replicates for every time
point. Each experiment was performed twice.
Liquid Chromatography-Mass Spectrometry
A Cogent Diamond Hydride Type C column (Gradient 3) was used to separate
metabolites as described previously (Pesek et al., 2009). An Agilent Accurate
Mass 6220 TOFwas coupled to an Agilent 1200 liquid chromatography system
for analysis. This configuration achieves mass errors of approximately 5 ppm,
mass resolution ranging from 10,000 to 25,000 (over m/z 121–955), and a 5
log10 dynamic range. Metabolite identities were queried using a mass
tolerance of <0.005 Da. Signal intensities were normalized within experiments
using acetyldiaminopimelate, acetylaminoadipate, indolepyruvate, aminooxo-
pimelate, and triose phosphate, 5 of the 74metabolites whose abundance was
unaffected by WR99210. Putative metabolite identities were based on accu-
rate mass (m/z) and chromatographic retention time matching. Metabolite
identities were verified by coelution with a chemical standard and metabolite
concentrations were calculated using the method of standard addition, where
available.828 Chemistry & Biology 21, 819–830, July 17, 2014 ª2014 Elsevier LRNA Preparation
RNA was isolated as described previously (Rustad et al., 2008). Briefly, pellets
were condensed from 40 ml of culture (OD600 0.1) and then resuspended in
TRIzol. The cells were lysed by bead beating, with cooling on ice between
steps. The cell lysates were then centrifuged, and the supernatant was trans-
ferred to a tube with Heavy Phase Lock Gel (Eppendorf North America) and
chloroform, inverted for 2 min, and then centrifuged at max speed for 5 min.
The aqueous phase was precipitated with isopranol and high salt solution
(0.8 M sodium citrate, 1.2 M NaCl). RNA was purified using an RNeasy kit
(Qiagen).
Microarray Analysis
RNA was converted to CyDye-labeled cDNA probes as described previously
(Rustad et al., 2008). For all experiments described here, 2 mg of total RNA
was used to generate probes. Sets of fluorescent probes were then hybridized
as previously described (Minch et al., 2012). Briefly, the arrays were custom
NimbleGen tiling arrays consisting of 135,000 probes spaced at100 bp inter-
vals around the MTB H37Rv genome (NCBI GEO accession number
GPL14896). Three biological replicate experiments were used for each drug
at each time point. Arrays were scanned, and spots were quantified using a
Genepix 4000B scanner with GenePix 6.0 software. These data were exported
to NimbleScan for mask alignment and ArrayStar for robust multichip average
(Bolstad et al., 2003) normalization and statistical analysis (NCBI GEO acces-
sion number GSE55979). Altered gene expression was considered significant
if it produced amoderated t test p < 0.01 and a log2 changeR 1 after Benjamini
Hochberg multiple testing correction.
Supplementation Assays
Supplemented stockmedia wasmade by adding filter sterilizedmetabolites to
7H9 for a final concentration of 2 mM for each individual metabolite. MTB
cultures constitutively expressing GFP as a reporter for growth were grown
to mid-log phase in 7H9 and then diluted to a calculated starting OD600 of
0.001 in supplemented media and dispensed into 96-well plates. Test com-
pounds in DMSO were added at 1% of total volume. Cells diluted 1:100 at
day 0, without drug treatment, were used to determine the MIC cutoff for
each assay. Plates were incubated for 7 days at 37C, with growth monitored
by fluorescence as described above. All results were confirmed by optical
density readings.
SUPPLEMENTAL INFORMATION
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